Leadership

President & CEO

Scott Briggs is a senior pharmaceutical commercial executive with over 25 years’ experience in pharmaceutical marketing and sales, strategic planning, and business management. Scott most recently served as Chief Commercial Officer of Sebela Pharmaceuticals, a specialty pharmaceutical company with market leading brands in gastroenterology, women’s health, and dermatology. In this role he led all commercial functions, substantially growing sales of its branded products, planned, and successfully implemented multiple product launches and acted as a senior member of the Executive Leadership team. Prior to joining Sebela Pharmaceuticals, Mr. Briggs served as Vice President, Marketing and Sales at Noven Pharmaceuticals, where he led all commercial operations. Previously, he also served Noven in the roles of Vice President – women’s health sales, and Executive Director – marketing and managed markets. Prior to joining Noven, Scott was senior director of marketing for JDS Pharmaceuticals. He also held several leadership positions in management and marketing with Ortho-McNeil Pharmaceuticals (part of Johnson & Johnson). Mr. Briggs holds a BA in Business Administration from Villanova University.

Chief Commercial Officer

Ed is a recognized leader in the pharmaceutical industry, with diversified, progressive experience centered around small to multibillion-dollar product launches and commercialization. He brings with him 20 years of experience in pharma and biotech with strong emphasis on business strategy, innovation, execution, and transformation. Ed’s most recent role was as SVP/GM at Currax Pharmaceuticals, which is an industry leader in the treatment of obesity and smoking cessation. In this capacity, he led the relaunch of a mature brand leading to new market inroads, while simultaneously planning for the commercialization of a new product. Before that, he had a very successful career with Novo Nordisk, Inc. (NNI) serving as an Leadership team member and Vice President, Head of Cardiometabolic portfolio where he directed the launches of Ozempic, Rybelsus and Wegovy.

Chief Financial Officer

Mark serves as our Chief Financial Officer and joined the company in 2022. He is a Certified Public Accountant with over 30 years of experience in publicly listed companies. Prior to joining Radius, Mark previously held senior leadership roles at Kaleido Biosciences, Valeritas, Inc., as well as Thermo Fisher Scientific, Inc.

Head of Human Resources

Joan serves as the company’s Head of Human Resources. She joined Radius in April 2021. She has over 25 years of human resources experience having worked in public and private organizations in the financial, manufacturing, healthcare, and clinical research industries. Prior to joining Radius, Joan was a Global HR Business Partner with PPD.

Global Chief Intellectual Property Counsel

Jim serves as the Chief intellectual property counsel at Radius Health. He joined Radius in June 2020. He is a global legal executive with extensive experience as a general legal and intellectual property strategist. Prior to joining Radius, Jim was Senior Vice President Intellectual Property at Novartis and Takeda / Shire.

U.S. Sales Channels

Danielle Holtschlag serves as Head of U.S. Sales Channels and joined the company in September 2021. She has over two decades of sales leadership experience including operations, training, and segment management. Prior to joining Radius, Danielle worked at PharmaEssentia and Genzyme.

Chief Medical Officer

Bruce Mitlak serves as our Chief Medical Officer and joined the company in 2016. Prior to Radius, Bruce was a Distinguished Medical Fellow at Eli Lilly and Company for more than two decades where he supported the development of novel treatments for musculoskeletal disorders and women’s health.

He has authored more than 90 original articles and chapters including publications in the New England Journal of Medicine and JAMA.

Corporate Finance

Peter Schwartzman leads our Corporate Finance efforts to actively manage the company’s capital structure and balance sheet. He joined the company in October 2020 and has more than two decades of portfolio and investment management experience. Prior to Radius, he worked at Piney Lake Capital Management, BlackRock, Alliance Capital Management, and Moody’s.

Chief Business Officer

Chhaya Shah has oversight of the company’s development and technical operations efforts for the abaloparatide and elacestrant assets and joined the company in July 2018. Prior to Radius, she was Senior Vice President at Synergy Pharmaceuticals as well as held significant leadership roles at Shire Pharmaceuticals, Wyeth Pharmaceuticals, and Abbott Laboratories.

Chhaya leads the company’s partnership and relationship with Menarini Group in support of the elacestrant molecule and program.

SVP / General Counsel

Erika Tooman, SVP / General Counsel, has more than two decades of legal pharmaceutical experience. An accomplished pharmaceutical executive and strategist, Erika oversees our corporate legal, intellectual property and compliance teams. She has wide-ranging experience in providing valuable legal perspective, establishing a clear vision, and implementing necessary strategy to achieve business goals. She previously served as General Counsel, Senior Vice President at Currax, where she continued to build her successful track record in corporate governance, risk management, intellectual property counseling and portfolio growth and management. She has also been a key contributor to the success of many licensing and M&A deals.

She is a recipient of the Healthcare Businesswomen’s Association Rising Star Award, is a registered patent attorney and is certified in healthcare compliance. Erika earned her JD from Brooklyn Law School, Master of Arts degree in Biotechnology from Columbia University, and Bachelor of Arts degree in Biology from Franklin & Marshall College. She is deeply involved in her local community and is a member of the Board of Directors for a local hospital in her community as well as a community college.

Business Intelligence & Digital – U.S. Commercial

Bob Valentine serves as Head of Business Intelligence & Digital for the U.S. Commercial group and joined the company in March 2021. Prior to Radius, Bob was a consultant in L.E.K. Consulting’s Life Sciences practice, focused on growth strategy, M&A, and operations & planning.

Bob has held various business roles at Shire, Regeneron, and Genzyme with experience in process engineering, business development, and operational execution.